高级搜索
伊立替康肝动脉化疗栓塞联合5-Fu/CF静脉化疗治疗结直肠癌肝转移的临床观察[J]. 肿瘤防治研究, 2009, 36(08): 696-698. DOI: 10.3971/j.issn.1000-8578.2009.08.019
引用本文: 伊立替康肝动脉化疗栓塞联合5-Fu/CF静脉化疗治疗结直肠癌肝转移的临床观察[J]. 肿瘤防治研究, 2009, 36(08): 696-698. DOI: 10.3971/j.issn.1000-8578.2009.08.019
Clinical Study of TACE with Irinotecan and Lipiodol Combining with Intravenous Chemotherapy of CF/5-Fu in Treatment of Hepatic Metastasis from Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(08): 696-698. DOI: 10.3971/j.issn.1000-8578.2009.08.019
Citation: Clinical Study of TACE with Irinotecan and Lipiodol Combining with Intravenous Chemotherapy of CF/5-Fu in Treatment of Hepatic Metastasis from Colorectal Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(08): 696-698. DOI: 10.3971/j.issn.1000-8578.2009.08.019

伊立替康肝动脉化疗栓塞联合5-Fu/CF静脉化疗治疗结直肠癌肝转移的临床观察

Clinical Study of TACE with Irinotecan and Lipiodol Combining with Intravenous Chemotherapy of CF/5-Fu in Treatment of Hepatic Metastasis from Colorectal Cancer

  • 摘要: 目的 评价伊立替康介入栓塞联合5-Fu/CF静脉化疗治疗结直肠癌肝转移的疗效和毒性。 方法 结直肠癌肝转移患者行TACE术,伊立替康(CPT-11)加超液化碘油化疗栓塞,介入完成后即行5-Fu/CF静脉化疗,每3周重复。 结果 全组26例患者共接受了98个周期化疗,平均4个周期(3~6周期)。CR 2例(7.69%),PR 8例(30.77%),SD 13例(50%),PD 3例(11.54%);临床获益率88.46%(23/26);中位疾病进展时间7.3月;中位生存期14.2月。最常见的毒副反应是中性粒细胞减少,消化道反应,多为Ⅰ~Ⅱ级。 结论 伊立替康肝动脉化疗栓塞联合CF/5-Fu静脉化疗治疗结直肠癌肝转移疗效肯定,毒性反应可以耐受。

     

    Abstract: Objective To evaluate the efficacy and toxicity of TACE using Irinotecan and lipiodol combining with intravenous CF/5-Fu in the treatment of hepatic metastasis from colorectal cancer. Methods Twenty six cases with hepatic metastasis from colorectal cancer were treated by the above-mentioned method, every three weeks was a cycle. Results Two cases had complete response, eight cases had partial response,thirteen cases had stable disease and three cases with progressive disease. Gross efficiency rate was 38.46% and the stability rate was 50%.The clinical beneficial response rate was 88.46%.Median time to progression was 7.3 months and median overall survival time was 14.2 months. The common treatment related adverse events were neutropenia and delayed diarrhea. Toxic effect was light. Conclusion TACE using Irinotecan and Lipiodol combining with intravenous CF/5-Fu in the treatment of hepatic metastasis from colorectal cancer is an effective and well tolerated regimen.

     

/

返回文章
返回